Precision BioSciences (DTIL) vs Veraxa Biotech (VRXA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Precision BioSciences (DTIL) has outperformed Veraxa Biotech (VRXA) over the past year, gaining 10.0% versus a loss of 88.5%. Precision BioSciences is the larger company by market cap ($175.0 million vs $168.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DTIL | VRXA |
|---|---|---|
| Share price | $6.34 | $1.19 |
| Market cap | $174.99M | $168.28M |
| 1-day change | +1.44% | -0.83% |
| YTD return | +50.24% | -88.75% |
| 1-year return | +10.04% | -88.53% |
| 5-year return | -97.87% | — |
| EPS (TTM) | $-1.35 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.62 | $27.36 |
| 52-week low | $3.53 | $1.04 |
| Distance from 52-week high | -34.10% | -95.65% |
| Analyst consensus | none | — |
| Avg. price target upside | +363.72% | — |
| Average volume | 293.42K | 274.75K |
| Shares outstanding | 27.60M | 141.41M |
| Employees | 67 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DTIL has outperformed VRXA by 98.6 percentage points over the past year.
About Precision BioSciences
DTIL stock →Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 67 employees
About Veraxa Biotech
VRXA stock →VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Health Care · Biotechnology: Pharmaceutical Preparations
DTIL vs VRXA FAQ
Which is bigger, Precision BioSciences or Veraxa Biotech?
Precision BioSciences (DTIL) is larger, with a market capitalization of $174.99M compared with $168.28M for Veraxa Biotech (VRXA).
Which stock has performed better over the past year, DTIL or VRXA?
DTIL returned +10.04% over the past 12 months, compared with -88.53% for VRXA (price return, excluding dividends). Past performance does not predict future results.
Are Precision BioSciences and Veraxa Biotech in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Precision BioSciences and Biotechnology: Pharmaceutical Preparations for Veraxa Biotech.